Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Background/Aims Infliximab is currently used for the treatment of moderate-to-severe ulcerative colitis (UC) with an inadequate response to conventional agents. The efficacy and safety of ...